Molecular Pathomechanisms and Biomarkers of Alzheimer's Disease
A special issue of Life (ISSN 2075-1729). This special issue belongs to the section "Physiology and Pathology".
Deadline for manuscript submissions: closed (28 June 2023) | Viewed by 1595
Special Issue Editors
Interests: Alzheimer's disease; autoimmunity; immunogenetics; neurodegenerative diseases; neuroinflammation; multiple sclerosis
Special Issues, Collections and Topics in MDPI journals
Interests: Alzheimer's disease; immunogenetics; HLA typing; neurodegenerative diseases
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Alzheimer's disease (AD) is a progressive neurodegenerative disorder and the leading cause of dementia in elderly people. With approximately 50 million cases worldwide, AD represents a major medical and socio-economic burden. The most common form of the disease is sporadic late-onset AD, which accounts for approximately 90% of all cases and typically develops after the age of 65. AD is a multifactorial disease that results from a complex interplay between environmental, lifestyle, genetic, and epigenetic factors. Despite significant advancements in recent decades, the exact cause of the disease and processes leading to the development of amyloid and tau pathology, neuroinflammation, neurodegeneration, and other AD-related abnormalities are still not fully understood. Efforts to uncover the key cellular and molecular players in the pathological process promise the establishment of new screening, diagnostic, predictive, and monitoring biomarkers for AD as well as the development of novel effective therapeutic strategies.
In this Special Issue, we aim to publish review and original research articles that could fuel the efforts to better understand the processes underlying AD development. We would like to invite submissions addressing a broad range of topics including, but not limited to, the following: genetic and epigenetic risk factors of AD, the role of innate and adaptive immune mechanisms, oxidative stress, hormones and metabolic alterations in AD development and progression, the link between the gut microbiome and AD, and new neuroimaging and biofluid-based biomarkers for AD diagnostics.
Dr. Juraj Javor
Dr. Ivana Shawkatová
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Life is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- Alzheimer's disease
- biomarkers, epigenetics
- genetics
- genomics
- immune mediators
- neurodegeneration
- neuroinflammation
- proteomics
- transcriptomics
